NOVO’S OZEMPIC® (SEMAGLUTIDE) 2 MG IS LINKED TO A LOWER RISK OF SERIOUS HEART-RELATED ISSUES (DEATH, HEART ATTACK, AND STROKE) IN ADULTS WITH TYPE 2 DIABETES THAN SWITCHING TO MOUNJARO® (TIRZEPATIDE), AS PER A REAL-WORLD STUDY PRESENTED AT EASD.